Patient and transplant characteristics
| Characteristic . | Entire cohort . | Chronic-phase . | Accelerated-phase . | P . |
|---|---|---|---|---|
| Patients, no. | 349 | 314 | 35 | |
| Age, y | .96 | |||
| Median (range) | 58 (18-74) | 58 (18-74) | 58 (39-72) | |
| Female sex, no. (%) | 133 | 130 (41) | 13 (37) | .38 |
| Myelofibrosis, no. (%) | .08 | |||
| Primary | 252 | 231 (74) | 21 (60) | |
| Secondary | 97 | 83 (26) | 14 (40) | |
| Blasts, % | ||||
| Median (range) | 1 (0-19) | 1 (0-8) | 14 (10-19) | |
| Hemoglobin, g/dL | .25 | |||
| Median (range) | 9.5 (6.1-17.9) | 9.6 (6.4-17.9) | 9.0 (6.1-13.2) | |
| WBC, ×109/L | .08 | |||
| Median (range) | 8.4 (0.6-168.8) | 8.1 (0.6-168.8) | 13.6 (1.9-56.4) | |
| Platelets, ×109/L | .70 | |||
| Median (range) | 145 (5-2437) | 149 (6-2437) | 115 (5-769) | |
| Constitutional symptoms, no. (%) | 209 | 184 (59) | 25 (71) | .10 |
| KPS, no. (%) | .02 | |||
| 90-100 | 238 | 220 (70) | 18 (51) | |
| <90 | 111 | 94 (30) | 17 (49) | |
| Cytogenetics, no. (%) | .99 | |||
| Favorable | 174 | 158 (79) | 16 (80) | |
| Unfavorable | 22 | 20 (10) | 2 (10) | |
| VHR | 24 | 22 (11) | 2 (10) | |
| Driver mutation, no. (%) | .90 | |||
| CALR | 67 | 61 (19) | 6 (17) | |
| JAK2 | 200 | 181 (58) | 19 (54) | |
| MPL | 23 | 20 (6) | 3 (9) | |
| Triple negative | 59 | 52 (17) | 7 (20) | |
| HMR, no. (%) | .86 | |||
| Present | 140 | 126 (40) | 14 (40) | |
| No. of mutations | .92 | |||
| Median (range) | 2 (0-6) | 2 (0-6) | 2 (1-4) | |
| DIPSS, no. (%) | .05 | |||
| Low | 15 | 15 (6) | 0 | |
| Intermediate-1 | 75 | 72 (31) | 3 (14) | |
| Intermediate-2 | 123 | 112 (49) | 11 (52) | |
| High | 39 | 32 (14) | 7 (34) | |
| MYSEC-PM, no. (%) | .49 | |||
| Low | 15 | 15 (18) | 0 | |
| Intermediate-1 | 46 | 40 (43) | 6 (43) | |
| Intermediate-2 | 21 | 18 (22) | 3 (21) | |
| High | 15 | 10 (12) | 5 (36) | |
| Donor relation, no. (%) | .36 | |||
| Matched related | 89 | 81 (26) | 8 (23) | |
| Matched unrelated | 174 | 152 (48) | 22 (63) | |
| Mismatched related | 2 | 2 (1) | 0 | |
| Mismatched unrelated | 84 | 79 (25) | 5 (14) | |
| Regimen | .92 | |||
| Busulfan-fludarabine | 293 | 264 (74) | 29 (83) | |
| Fludarabine-melphalan | 55 | 49 (15) | 6 (17) | |
| TBI-fludarabine | 1 | 1 (1) | 0 | |
| Time to transplant, y | .36 | |||
| Median (range) | 2.2 (0.1-47.3) | 2.1 (0.1-47.3) | 3.2 (0.2-47.2) | |
| Ruxolitinib pretransplant, no. (%) | 117 | 102 (33) | 15 (43) | .26 |
| Follow-up, y | .62 | |||
| Median (range) | 6.0 (5.2-6.7) | 6.0 (5.2-6.7) | 5.9 (2.8-9.0) |
| Characteristic . | Entire cohort . | Chronic-phase . | Accelerated-phase . | P . |
|---|---|---|---|---|
| Patients, no. | 349 | 314 | 35 | |
| Age, y | .96 | |||
| Median (range) | 58 (18-74) | 58 (18-74) | 58 (39-72) | |
| Female sex, no. (%) | 133 | 130 (41) | 13 (37) | .38 |
| Myelofibrosis, no. (%) | .08 | |||
| Primary | 252 | 231 (74) | 21 (60) | |
| Secondary | 97 | 83 (26) | 14 (40) | |
| Blasts, % | ||||
| Median (range) | 1 (0-19) | 1 (0-8) | 14 (10-19) | |
| Hemoglobin, g/dL | .25 | |||
| Median (range) | 9.5 (6.1-17.9) | 9.6 (6.4-17.9) | 9.0 (6.1-13.2) | |
| WBC, ×109/L | .08 | |||
| Median (range) | 8.4 (0.6-168.8) | 8.1 (0.6-168.8) | 13.6 (1.9-56.4) | |
| Platelets, ×109/L | .70 | |||
| Median (range) | 145 (5-2437) | 149 (6-2437) | 115 (5-769) | |
| Constitutional symptoms, no. (%) | 209 | 184 (59) | 25 (71) | .10 |
| KPS, no. (%) | .02 | |||
| 90-100 | 238 | 220 (70) | 18 (51) | |
| <90 | 111 | 94 (30) | 17 (49) | |
| Cytogenetics, no. (%) | .99 | |||
| Favorable | 174 | 158 (79) | 16 (80) | |
| Unfavorable | 22 | 20 (10) | 2 (10) | |
| VHR | 24 | 22 (11) | 2 (10) | |
| Driver mutation, no. (%) | .90 | |||
| CALR | 67 | 61 (19) | 6 (17) | |
| JAK2 | 200 | 181 (58) | 19 (54) | |
| MPL | 23 | 20 (6) | 3 (9) | |
| Triple negative | 59 | 52 (17) | 7 (20) | |
| HMR, no. (%) | .86 | |||
| Present | 140 | 126 (40) | 14 (40) | |
| No. of mutations | .92 | |||
| Median (range) | 2 (0-6) | 2 (0-6) | 2 (1-4) | |
| DIPSS, no. (%) | .05 | |||
| Low | 15 | 15 (6) | 0 | |
| Intermediate-1 | 75 | 72 (31) | 3 (14) | |
| Intermediate-2 | 123 | 112 (49) | 11 (52) | |
| High | 39 | 32 (14) | 7 (34) | |
| MYSEC-PM, no. (%) | .49 | |||
| Low | 15 | 15 (18) | 0 | |
| Intermediate-1 | 46 | 40 (43) | 6 (43) | |
| Intermediate-2 | 21 | 18 (22) | 3 (21) | |
| High | 15 | 10 (12) | 5 (36) | |
| Donor relation, no. (%) | .36 | |||
| Matched related | 89 | 81 (26) | 8 (23) | |
| Matched unrelated | 174 | 152 (48) | 22 (63) | |
| Mismatched related | 2 | 2 (1) | 0 | |
| Mismatched unrelated | 84 | 79 (25) | 5 (14) | |
| Regimen | .92 | |||
| Busulfan-fludarabine | 293 | 264 (74) | 29 (83) | |
| Fludarabine-melphalan | 55 | 49 (15) | 6 (17) | |
| TBI-fludarabine | 1 | 1 (1) | 0 | |
| Time to transplant, y | .36 | |||
| Median (range) | 2.2 (0.1-47.3) | 2.1 (0.1-47.3) | 3.2 (0.2-47.2) | |
| Ruxolitinib pretransplant, no. (%) | 117 | 102 (33) | 15 (43) | .26 |
| Follow-up, y | .62 | |||
| Median (range) | 6.0 (5.2-6.7) | 6.0 (5.2-6.7) | 5.9 (2.8-9.0) |
DIPSS, Dynamic International Prognostic Scoring System; HMR, high molecular risk; KPS, Karnofsky performance score; MYSEC-PM, secondary myelofibrosis prognostic model; no., number; TBI, total-body irradiation; VHR, very high risk.